Filters
Individuals who regularly consume high-fat dairy are at greater risk of death due to chronic liver diseases (CLD), reveals a recent study. However, low-fat dairy intake may lower such risk.
The presence of substantial hepatic steatosis estimated by controlled attenuated parameter (CAP) score among patients who underwent vibration-controlled transient elastography (VCTE) appears to reduce the risk of all-cause mortality and decompensation, particularly in those with metabolic dysfunction-associated steatotic liver disease (MASLD), reports a study.
The use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitor helps lower the incidence of serious liver events among patients with cirrhosis who are receiving diuretic therapy, according to a study.
Liver injury occurs in around one in 20 patients treated with cyclin-dependent kinase 4/6 inhibitors for metastatic breast cancer, according to a multicentre retrospective study in Spain.
Alanine aminotransferase (ALT) appears to be a useful primary screening measure to identify early signs of fibrosis, such as increased liver stiffness, in children with overweight or obesity and additional risk factors, according to a study.
A phase II study has demonstrated the safety of faecal microbiota transplantation (FMT) in patients with cirrhosis treated with lactulose and rifaximin, with no related adverse events (AEs) seen. FMT also results in lower rates of hepatic encephalopathy (HE) recurrence.
The presence of diabetes mellitus predisposes patients with chronic hepatitis B (CHB) to a higher risk of developing hepatocellular carcinoma (HCC), reveals a study presented at EASL 2025.
The use of the injectable extended-release naltrexone for alcohol use disorder in patients with advanced alcohol-associated liver disease (ALD) does not appear to carry a substantial hepatotoxicity or liver decompensation risk, according to a study.
A recent study has provided data bolstering the current recommendation of using carvedilol to prevent a first decompensation of cirrhosis in patients with compensated cirrhosis.
Metabolic burden in patients with chronic hepatitis B (CHB) and concurrent steatotic liver disease (SLD) may exacerbate the risks of all-cause, liver-related, and cardiovascular mortality, suggests a study.